Ignite Creation Date:
2024-10-25 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06610409
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity
Detailed Description:
Systemic lupus erythematosus SLE is a common autoimmune disease involving multiple organs and systems SLE is characterized by the production of a large number of autoantibodies and the deposition of various immune complexes in target tissue 12
Chemokines are a large family of small secreted proteins that are identified as attractants of different types of leukocytes including neutrophils to sites of infection and inflammation They are produced locally in tissues and act through interaction with specific G protein-coupled receptors that are predominantly expressed on leukocytes345 Interaction between chemokines and their receptor plays an essential role in the development and homeostasis of the immune system as well as inflammatory response 6 Although most chemokines promote locomotion of immune cells some of them might inhibit leukocyte migration under certain circumstances 7
We found in a study that serum CXCL5 levels were significantly lower in SLE patients than in healthy individuals and were negatively correlated with disease activity By administering CXCL5 intravenously in a mouse model of lupus mouse survival improved and indices of disease activity reduced significantly89 This finding suggests that homeostatic chemokines in peripheral blood might play an anti- inflammatory role and that serum levels of anti- inflammatory chemokines such as CXCL5 would be decreased in patients with autoimmune diseases 7
So in this study we aim to determine level of CXCL5 in SLE patients association of chemokine levels with demographics clinical and laboratory investigations of patients and its correlation with disease activity 7
Chemokines are a large family of small secreted proteins that are identified as attractants of different types of leukocytes including neutrophils to sites of infection and inflammation They are produced locally in tissues and act through interaction with specific G protein-coupled receptors that are predominantly expressed on leukocytes345 Interaction between chemokines and their receptor plays an essential role in the development and homeostasis of the immune system as well as inflammatory response 6 Although most chemokines promote locomotion of immune cells some of them might inhibit leukocyte migration under certain circumstances 7
We found in a study that serum CXCL5 levels were significantly lower in SLE patients than in healthy individuals and were negatively correlated with disease activity By administering CXCL5 intravenously in a mouse model of lupus mouse survival improved and indices of disease activity reduced significantly89 This finding suggests that homeostatic chemokines in peripheral blood might play an anti- inflammatory role and that serum levels of anti- inflammatory chemokines such as CXCL5 would be decreased in patients with autoimmune diseases 7
So in this study we aim to determine level of CXCL5 in SLE patients association of chemokine levels with demographics clinical and laboratory investigations of patients and its correlation with disease activity 7
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None